Test ID WARSV Warfarin Response Genotype, Varies
Advisory Information
If patient is using medications other than warfarin, the preferred test is 2C9GV / Cytochrome P450 2C9 Genotype, which tests for only the CYP2C9 gene.
Testing is available as the single gene assay (this test) or as a part of a focused pharmacogenomics panel, which includes testing for the following genes: CYPs 1A2, 2C9, 2C19, 2D6, 3A4, 3A5, 4F2, SLCO1B1, and VKORC1. Order PGXFP / Focused Pharmacogenomics Panel if multiple pharmacogenomic genotype testing is desired.
Specimen Required
Multiple genotype tests can be performed on a single specimen after a single extraction. See Multiple Genotype Test List in Special Instructions for a list of tests that can be ordered together.
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send specimen in original tube.
Specimen Stability Information: Ambient (preferred)/Refrigerated
Specimen Type: Saliva
Patient Preparation: Patient should not eat, drink smoke, or chew gum 30 minutes prior to collection.
Supplies: Saliva Swab Collection Kit (T786)
Specimen Volume: 1 swab
Collection Instructions: Collect and send specimen per kit instructions.
Specimen Stability Information: Ambient
Specimen Type: DNA
Container/Tube: 2 mL screw top tube
Specimen Volume: 100 mcL (microliters)
Collection Instructions:
1. The preferred volume is 100 mcL at a concentration of 50 ng/mcL.
2. Include concentration and volume on tube.
Specimen Stability Information: Frozen (preferred)/Ambient/Refrigerated
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Cardiovascular Test Request (T724)
-Neurology Specialty Testing Client Test Request (T732)
-Therapeutics Test Request (T831)
Useful For
Identifying patients who may require warfarin dosing adjustments(3,4) including:
-Patients being started on a first prescription for warfarin
-Patients who have previously been prescribed warfarin and have required multiple dosing adjustments to maintain the international normalized ratio in the target range
-Patients with a history of thrombosis or bleeding when taking warfarin
Genetics Test Information
This test is used for assessing CYP2C9, VKORC1, CYP4F2, and rs12777823 for variants affecting the metabolism of warfarin (Coumadin). This assay should be ordered on patients who are receiving warfarin for the first time or who are experiencing difficulties in maintaining the international normalized ratio (INR) in the therapeutic range.
Special Instructions
Method Name
Real-Time Polymerase Chain Reaction (PCR) with Allelic Discrimination Analysis
Reporting Name
Warfarin Response GenotypeSpecimen Type
VariesSpecimen Minimum Volume
Blood: 0.4 mL
Saliva: 1 swab
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Reference Values
An interpretive report will be provided.
Day(s) and Time(s) Performed
Monday through Friday; 8 a.m.
Performing Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
0030U
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
WARSV | Warfarin Response Genotype | 93196-4 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
BA0251 | CYP2C9 Genotype | 46724-1 |
BA0248 | VKORC1 Genotype | 50722-8 |
BA0232 | Additional VKORC1 Variants | 50722-8 |
BA0254 | CYP4F2 *3 Genotype | 93197-2 |
BA0257 | rs12777823 Genotype | 93198-0 |
BA0234 | Interpretation | 69047-9 |
BA0260 | Additional Information | 48767-8 |
BA0236 | Method | 49549-9 |
BA0237 | Disclaimer | 62364-5 |
BA0238 | Reviewed by | 18771-6 |